Searching for a job is often very frustrating, and can lead to many a sleepless night especially without a solid plan in place. Sarah Goddard, the UK Recruitment Director at Clinical Professionals spoke with Applied Clinical Trials recently about hiring trends in the clinical trial area and how to best prepare for a job search.
What are the current hiring trends in the clinical trial space?
We predominantly work with pharmaceuticals, biotechs, and CROs. January was quite quiet, but February and March have been very busy. We have had a lot of clinical research contract roles come through. We are getting around 10 to 20 vacancies a week across clinical research, regulatory, drug safety, medical information, and biometrics. At the moment most the positions are contracts—a lot of companies have an eye on headcount and are increasingly looking to hire contractors.
Are you noticing any particular positions that are hot at the moment?
Clinical monitors; medical scientific liaisons; health economics and market access; and regulatory affairs, especially for people with emerging market experience.
Where do you see the sector going in three to five years? And how can clinical trial workers prepare for the future?
There will be a big market in the United Kingdom and the rest of Europe. Also, the emerging markets will play an important role. If someone can get experience working on global studies it would be very helpful.
Also, health economics and market access is a very big growth area at the moment. A lot of our clients are expecting big growth in this area in 2012 and 2013 in terms of hiring.
How can someone get relevant emerging market experience?
It is quite difficult to get that experience; most employers would like you to have some level of experience prior to placement. It is important to target those companies that have those departments. Get your foot the door and try to gain access.
Do you have any advice for people just starting out?
If you have a good life sciences degree the best thing you can do is get into industry and get some experience. Certainly in the United Kingdom experience is very important. Academics is all well in good, but real-word exposure is important. Try to network as a graduate or even while you are still in school. Do some volunteer work if necessary; it is all about getting your foot in the door. A lot of employers are looking for entry-level employees, and it is very competitive.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
New FDA Initiative Reveals Common Reasons for Drug Application Rejection
July 11th 2025By publishing more than 200 complete response letters, the FDA is offering new visibility into the issues that most often delay drug approvals, including safety concerns, trial design flaws, and manufacturing gaps.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.